

FOIA MARKER

This is not a textual record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

Collection/Record Group: Clinton Presidential Records

Subgroup/Office of Origin: National AIDS Policy Office

Series/Staff Member:

Subseries:

OA/ID Number: 21068

FolderID:

Folder Title:

Pfizer

Stack:

S

Row:

67

Section:

1

Shelf:

3

Position:

2

Corporate Affairs Division
Pfizer Inc.
325 - 7th Street, NW
Suite No 1200
Washington, DC 20004
Tel 202 783 7070



June 5th

Catherine P. Bennett
Vice President
Federal Tax and Trade Legislation

Dear Sandy,

It was a pleasure meeting with you last week. As promised, I enclose a brochure on Pfizer's Trachanz program. I also spoke with our Diflucon team. As soon as they feel ready to share the more specific outlines of our program with you, I will be in touch. Again, I enjoyed talking to you.

Sincerely,

Cathie

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a publication.


Publications have not been scanned in their entirety for the purpose of digitization. To see the full publication please search online or visit the Clinton Presidential Library's Research Room.

Trachoma is the
cause of preventable blindness.

Almost 150 million people are blind due to trachoma. It is the leading cause of preventable blindness in Africa, Asia, the Americas, and Australia. Trachoma is caused by a bacterium called Chlamydia trachomatis. It is spread easily from one person to another by hand contact or by flies that are attracted to runny noses. Repeated infections eventually cause the eyelids to turn inward and rub against the eyeball, leading to blindness.

International TRACHOMA Initiative

**Dedicated to Eliminating the World's
Leading Cause of Preventable Blindness**



Founded by

The Edna McConnell Clark Foundation

and Pfizer Inc.

0. 9/1/98



U.S. Agency for International Development
Washington, D.C. 20523

USAID MISSION TO UGANDA
P.O. BOX 7856
KAMPALA, UGANDA

FACSIMILE TRANSMITTAL COVER SHEET

DATE: 3/15/00

TO:

ATTENTION: Sandra Thurman

ORGANIZATION: ONAP

FAX PHONE: 202-456-2438

OFFICE PHONE: 202-456-2441

FROM:

ORIGINATOR: Dawn Liberi, DIR

ORGANIZATION: USAID/Kampala

FAX PHONE: 256-41-
258988/233417/258981

OFFICE PHONE: 254-41-235879

SUBJECT:

NUMBER OF PAGES *(including this cover sheet):* 2

COMMENTS: Attached is a copy of the letter to Pfizer from the Uganda AIDS Commission.
Dawn.

*Sorry -
Hope you had a good trip to
Kampala! Let's try to talk.
Are you coming here after Sandra
- yes?
Dawn*



Uganda AIDS Commission Secretariat

Plot 213 Sentema Road, P.O. Box 10779, KAMPALA - UGANDA. Tel: 273538/273231; Fax: 258173; E-mail: uacnadic@mul.com

Our Ref.: UAC/DGO/PFIZER

Your Ref.:

23 June, 2000

Mr Barry Smith
Chief Executive Officer
Pfizer Inc.
SOUTH AFRICA
Fax # 000-27-11-7830912

Dear Mr Smith

A PARTNERSHIP FOR COMBATING THE HIV/AIDS EPIDEMIC IN UGANDA

Uganda is one of the countries most affected by the HIV/AIDS epidemic. It is estimated that about 1.7 million people are infected with HIV in Uganda. These will subsequently progress to full-blown AIDS with all the attendant opportunistic infections like TB, Cryptococcal meningitis, etc.

One of the strategic frameworks adopted by the Government of Uganda in combating HIV/AIDS is "increasing access to drugs for opportunistic infections" for all those affected by HIV/AIDS in order to improve their quality of life.

The Ministry of Health notes with concern the increasing numbers of HIV positive individuals manifesting with Cryptococcal meningitis. It is estimated that about 115,000 persons are affected by this condition countrywide annually. The cost implications of treating these individuals are enormous, since the annual cost of Fluconazole per patient is more than ten times per capita income of Ugandans.

It is in this regard, therefore, that the Government of Uganda would like to explore all possibilities of establishing a partnership programme with Pfizer including the potential for donations of Fluconazole to Uganda. Benefits of such a partnership would include not only improved quality of life for patients but also economic improvements for patients and the Government from reduced treatment costs, reduced illness and death, postponed orphaned for children, and reduced dependency on families and Government.

We would appreciate a meeting, at your earliest convenience, between the Ministry of Health, Uganda AIDS Commission and other interested partners, to explore the possibility of establishing the partnership.

Yours sincerely

Dr David N Kihumuro Apuuli
DIRECTOR GENERAL

c.c. Hon. Dr Ruhakana Rugunda, Minister In-Charge of the Presidency
Hon Dr C W C B Kiyonga, Minister of Health
Dr J Kagimba, Senior Presidential Advisor on HIV/AIDS
The Chairman, Uganda AIDS Commission
Sandy Thurman, AIDS Policy Advisor, White House
Kathy Bennett, Pfizer, Washington D.C., Fax # 000-1-202-783-7070
Sandy Thurman, AIDS Policy Advisor, White House

Acad/Letter/Doc/10